KNOTUS Co.Ltd Total Assets
KNOTUS Co.Ltd total assets. Based on the latest financial reports, KNOTUS Co.Ltd (278650) holds total assets worth ₩156.41 Billion KRW (≈ $106.00 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see KNOTUS Co.Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of KNOTUS Co.Ltd (2016–2024)
Total assets of KNOTUS Co.Ltd from 2016 to 2024. This chart illustrates how KNOTUS Co.Ltd's total assets have evolved over time, based on quarterly financial data. See 278650 stock price for real-time trading data and today's change.
KNOTUS Co.Ltd - Asset Composition Analysis
KNOTUS Co.Ltd Total Assets Breakdown (December 2024)
KNOTUS Co.Ltd total assets breakdown as of December 2024. KNOTUS Co.Ltd's total assets of ₩156.41 Billion consist of 37.1% current assets and 62.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩46.15 Billion | 0.0% |
| Accounts Receivable | ₩11.12 Billion | 6.6% |
| Inventory | ₩1.51 Billion | 0.9% |
| Property, Plant & Equipment | ₩52.09 Billion | 31.0% |
| Intangible Assets | ₩3.49 Billion | 2.1% |
| Goodwill | ₩6.49 Billion | 3.9% |
Asset Composition Trend (2016–2024)
This chart illustrates how KNOTUS Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore KNOTUS Co.Ltd current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: KNOTUS Co.Ltd's current assets represent 37.1% of total assets in 2024, a decrease from 44.3% in 2016.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 24.9% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 7.0% in 2016.
- Asset Diversification: The largest asset category is property, plant & equipment at 31.0% of total assets.
KNOTUS Co.Ltd Competitors by Total Assets
Key competitors of KNOTUS Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
KNOTUS Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.29 | 1.37 | 1.86 |
| Quick Ratio | 1.25 | 1.34 | 1.71 |
| Cash Ratio | 0.00 | 1.01 | 0.00 |
| Working Capital | ₩11.37 Billion | ₩16.69 Billion | ₩13.20 Billion |
KNOTUS Co.Ltd - Advanced Valuation Insights
This section examines the relationship between KNOTUS Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.0% |
| Total Assets | ₩168.33 Billion |
| Market Capitalization | $290.80 Million USD |
Valuation Analysis
Below Book Valuation: The market values KNOTUS Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: KNOTUS Co.Ltd's assets decreased by 2.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for KNOTUS Co.Ltd (2016–2024)
The table below shows the annual total assets of KNOTUS Co.Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩168.33 Billion ≈ $114.07 Million |
-1.97% |
| 2023-12-31 | ₩171.71 Billion ≈ $116.37 Million |
-0.27% |
| 2022-12-31 | ₩172.19 Billion ≈ $116.69 Million |
+81.97% |
| 2021-12-31 | ₩94.63 Billion ≈ $64.13 Million |
+27.50% |
| 2020-12-31 | ₩74.22 Billion ≈ $50.29 Million |
+20.62% |
| 2019-12-31 | ₩61.53 Billion ≈ $41.70 Million |
+40.67% |
| 2018-12-31 | ₩43.74 Billion ≈ $29.64 Million |
+33.68% |
| 2017-12-31 | ₩32.72 Billion ≈ $22.17 Million |
+67.56% |
| 2016-12-31 | ₩19.53 Billion ≈ $13.23 Million |
-- |
About KNOTUS Co.Ltd
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more